Tamsulosin and Prostate-Specific Antigen Levels

Introduction to Tamsulosin and 5-Alpha-Reductase Inhibitors

The National Comprehensive Cancer Network recommends distinguishing tamsulosin from 5-alpha-reductase inhibitors (5-ARIs) when considering effects on prostate-specific antigen (PSA) levels, as 5-ARIs such as finasteride and dutasteride reduce PSA levels by approximately 50% within 6-12 months of initiating therapy, whereas tamsulosin does not have this effect 1, 2
5-ARIs block the conversion of testosterone to dihydrotestosterone (DHT), which significantly reduces PSA levels, with studies showing only 35% of men demonstrate the expected 40-60% decrease in PSA after 12 months of treatment 2, 3, 4

The CombAT trial showed that dutasteride plus tamsulosin reduced prostate cancer incidence by 40% compared to tamsulosin alone, indicating that the PSA-lowering effect was attributable to dutasteride, not tamsulosin 3
When monitoring PSA in patients taking tamsulosin, no PSA adjustment is necessary for patients on tamsulosin alone, and standard PSA thresholds for prostate cancer screening should be used 5
For patients on combination therapy with tamsulosin and a 5-ARI, the PSA-lowering effect is attributable to the 5-ARI component, not tamsulosin, and the PSA reduction in these cases should be attributed to the 5-ARI effect 2, 3

Other factors can affect PSA levels independent of medication, including infection, recent instrumentation, ejaculation, or trauma 2
Herbal supplements such as saw palmetto may contain phytoestrogenic compounds that can affect PSA levels, and ketoconazole can lower PSA levels by inhibiting the androgen synthesis pathway 2, 3